203

The European Commission provided data with the responses to the public consultation. This information has been processed under the supervision of the European Commission (DG MARE unit C-1), acting as controller. Appropriate measures have been taken to ensure confidentiality and security in the processing operations, as stipulated in the Framework Contract MARE/2012/06 between the European Commission and ECORYS and consortium partners. A "Feedback Statement" with a comprehensive overview and analysis of the consultation's results will be prepared the European Commission, to be published in its website. Perceived barriers to growth Stakeholders have been asked to rank what they consider to be the main barrier in the commercialisation of products. In both categories a number of barriers have been identified by the European Commission and respondents have been asked to mark their importance on a scale of 17 where 1 is the most and 7 is the least important. Our analysis is twofold, on the one hand we have looked at what respondent have marked as the most significant barrier and in the next stage we have compared the findings with the percentage of responses that have ranked barriers as being 1-4 place. While we do not expect the rankings of barriers to be fundamentally different, however the numbers behind the individual barriers can be stronger, more pronounced if we look at how many stakeholders have ranked a specific challenge amongst the first four. Table 0.29 Market application: What are the greatest challenges in bringing marine biotechnology applications into the market? (% of responses) Ranked as the most Barriers to market application Access to finance Legal framework (e.g. administrative hurdles related to product development, intellectual property rights and ownership barriers) High risk involved Lack of knowledge (by traditional biotechnology players) about the potential of marine genetic resources for biotechnology applications Lack of collaboration including between academic and industrial partners / difficulty in finding partners for collaboration Lack of established marine biotechnology value chains or entry points in the already existing ones Lack/absence of support mechanisms (e.g. innovation incubators, etc.) Capacity shortage (e.g. suitably trained personnel, etc.) Lack of visibility of the sector Other significant barrier (1st place) 27.57% 20.24% 7.14% Ranked among as an important barrier (1st to 4th place) 63.10% 47.62% 40.48% 5.95% 32.14% 5.95% 30.95% 2.38% 30.95% 2.38% 1.29% 4.76% 1.19% 28.57% 21.43% 17.86% 5.95% Study in support of Impact Assessment work on Blue Biotechnology 173

204 Publizr Home